Palantir Pressured UK Health Officials to Access NHS GP Records
Palantir Lobbying Campaign Targets NHS GP Records Access
An investigation has uncovered that Palantir, the US-based data analytics firm, engaged in direct lobbying efforts to persuade UK health officials to grant its AI systems access to NHS GP records. The campaign, which sought to expand Palantir's existing influence within the National Health Service, raised significant concerns among medical professionals about patient confidentiality and institutional trust. Despite GP data being explicitly excluded from Palantir's current £330 million contract with NHS England, the company pursued this expansion through informal channels including WhatsApp communications with a senior health minister.
Details of the WhatsApp Pressure Campaign
According to exclusive correspondence, representatives from Palantir utilized direct messaging to communicate their position to Zubir Ahmed MP, a health ministry official. The company presented its case with considerable confidence, arguing that "the logic of joining up primary and secondary care data is unarguable" and insisted that its proprietary software represented the "ideal" solution for integrating such information systems. These communications occurred in February 2026, demonstrating an active, sustained effort to reshape the boundaries of Palantir's involvement with the NHS infrastructure.
The Original Contract Scope and Restrictions
Palantir currently operates the federated data platform (FDP) for NHS England under a substantial contract worth £330 million. This arrangement was specifically structured to exclude general practice records from the company's purview. The original agreement reflected deliberate policy choices made by NHS leadership and government officials, who determined that primary care data—the most sensitive patient information held by GPs—should remain outside of Palantir's technological ecosystem. The company's push to extend into this territory directly contradicted these established boundaries.
Medical Community Concerns and Patient Trust Issues
The prospect of allowing Palantir access to NHS GP records has generated considerable apprehension within the medical profession. General practitioners have expressed serious concerns that such an expansion would fundamentally undermine patient confidence in the healthcare system. These concerns stem from multiple considerations: the sensitive nature of GP records, which contain highly personal health information; the involvement of a private US corporation with historical ties to controversial surveillance practices; and the implications for data governance when information flows beyond traditional NHS boundaries.
Peter Thiel's Connection to Palantir
Adding another layer of political sensitivity to this situation is the fact that Palantir was co-founded by Peter Thiel, a billionaire technology entrepreneur with well-documented support for Donald Trump and involvement in right-wing political circles. This association has prompted heightened scrutiny regarding the company's operations and influence within the NHS, as critics question whether US corporate interests and political ideologies might influence how sensitive British health data is managed and utilized.
The Federated Data Platform and NHS Operations
The federated data platform represents Palantir's primary NHS initiative, with the company claiming its system has contributed to measurable improvements in healthcare delivery. According to Palantir's assertions, the technology has facilitated reductions in surgical waiting times and addressed discharge delays across NHS facilities. However, these claimed benefits do not necessarily justify extending the company's access into general practice records, which serve different clinical functions and contain different categories of sensitive information.
Distinction Between Primary and Secondary Care Data
Primary care data from GP practices contains comprehensive, longitudinal health records for individual patients, including mental health information, reproductive history, and other particularly sensitive details. Secondary care data from hospitals and specialists, while important, represents episodic treatment information. The integration of these two categories under Palantir's platform would create an unprecedented consolidated database of personal health information accessible through a private US corporation.
Official Response and Policy Implications
The revelation of this lobbying campaign raises important questions about corporate influence within NHS governance and the formal structures meant to protect patient data. Health officials and policymakers must now address whether informal lobbying through personal messaging channels represents an appropriate mechanism for discussing expansions of corporate data access, or whether such discussions should occur only through formal, transparent, and publicly accountable processes.
The incident highlights ongoing tensions between the NHS's need for technological innovation and data integration capabilities, and the imperative to maintain strict safeguards protecting patient privacy and institutional independence. As the health service continues to digitize and optimize its operations, decisions about which private companies access which categories of data carry profound implications for public trust and healthcare outcomes.
Broader Context of NHS Data Governance
This situation reflects broader debates within Britain's health system regarding data sharing, technological modernization, and the role of private corporations in public healthcare infrastructure. The NHS has increasingly relied on private sector expertise to manage its complex data systems, yet this dependency creates vulnerabilities and raises governance questions. The Palantir situation exemplifies the delicate balance required when inviting private entities to participate in managing the nation's most sensitive health information.
